This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myocarditis in Diseases Classified Elsewhere달리 분류된 질환에서의 심근염 (타분류질환의 심근염)

📋 Contents and key points
Secondary myocarditis, myocarditis associated with systemic disease, Chagas myocarditis, sarcoid myocarditis, lupus myocarditis, Lyme myocarditis
ItemDetails
A. Classification codesICD-10: I41 (Myocarditis in diseases classified elsewhere) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: copayment 5% for up to 30 days from the registration date)
B. Synonyms
C. Adult onsetPresents as myocardial involvement during the course of an underlying systemic disease. Chagas disease is an important cause in adults in Central and South America, and sarcoidosis and lupus occur mainly in middle-aged adults.
1. HistoryHistory of descriptions of Chagas heart disease (Carlos Chagas, 1909), sarcoid heart disease, and SLE myocardial involvement; development of recognition of myocarditis by underlying disease
2. CausesChagas disease (Trypanosoma cruzi), sarcoidosis, SLE, Lyme disease (B. burgdorferi), diphtheria toxin, toxoplasmosis
3. GeneticsHLA-DRB1*03, *04 associations in sarcoidosis; HLA-DR3 and C4A deficiency in SLE; HLA polymorphisms in Chagas susceptibility
4. General epidemiologyChagas heart disease accounts for about 30~40% of heart failure causes in Central and South America; clinical cardiac involvement in about 5~10% of patients with sarcoidosis
5. PathophysiologyDirect parasite invasion (Chagas); non-caseating granulomatous infiltration (sarcoid); immune complex and complement activation (SLE); neurotoxin (diphtheria)
6. SymptomsConduction disturbances and arrhythmias (sarcoid, Chagas, Lyme), heart failure, chest pain; accompanied by systemic symptoms of the underlying disease
7. SignsAtrioventricular block (Lyme, sarcoid), ventricular enlargement, signs of heart failure, signs specific to the underlying disease (skin rash, arthritis, etc.)
8. ScreeningSerologic testing of people from Chagas-endemic areas; ECG, echocardiography, and cardiac MRI screening at diagnosis of sarcoidosis; monitoring of cardiac enzymes during SLE follow-up
9. DiagnosisSerum antibody tests (Chagas, Lyme), cardiac MRI (LGE pattern), endomyocardial biopsy (sarcoid granulomas), FDG-PET/CT
10. TreatmentChagas: benznidazole, nifurtimox (acute phase); sarcoid: corticosteroids; Lyme: doxycycline, ceftriaxone; GDMT for heart failure
11. PrognosisVaries with the underlying disease and extent of myocardial involvement; Chagas heart disease is a major cause of heart failure and sudden death in Central and South America; risk of sudden death in sarcoid heart disease
12. PreventionChagas vector control (insecticides, housing improvement); Lyme disease prevention (tick protection during outdoor activities); active control of underlying autoimmune disease
13. ReferencesNunes MCP et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management … and 9 other papers

1. History

The history of myocarditis in diseases classified elsewhere parallels the development of recognition of cardiac involvement in each underlying disease. Historically the most important is Chagas disease, described in 1909 by the Brazilian physician Carlos Chagas. He single-handedly discovered that the protozoan Trypanosoma cruzi is transmitted by the vector insect (Triatoma, a bug), directly invades the myocardium in the acute phase, and causes chronic Chagas heart disease after a latency period of decades. This is regarded as an unprecedented discovery in history that described the pathogen, vector, and clinical manifestations at the same time.

Cardiac sarcoidosis began to be described in the mid-20th century as the possibility of systemic involvement in sarcoidosis was recognized. In 1958, Bjerke et al. defined cardiac sarcoidosis as an independent clinical entity, and a strong association with conduction disturbances and sudden death was subsequently established. In the 1970s~80s, as cardiac sarcoidosis was reported at particularly high frequency in Japan, interest in racial differences grew. Currently, advances in cardiac MRI and FDG-PET/CT have greatly improved the noninvasive diagnosis of cardiac sarcoidosis.

Lyme heart disease was described as part of Lyme disease research that began with the 1975 investigation of a cluster of arthritis cases in Lyme, Connecticut, USA. After Burgdorfer discovered the causative organism Borrelia burgdorferi in 1982, the pathophysiology of Lyme heart disease was elucidated, and atrioventricular block was established as the most characteristic cardiac manifestation of Lyme heart disease. Myocardial involvement in SLE and other autoimmune diseases was gradually recognized as research accumulated on the potential for systemic involvement in these diseases, and cardiac-related morbidity in SLE patients is now recognized as an important factor determining disease prognosis.


2. Causes

The underlying diseases causing myocarditis classified under ICD I41 are as follows. Chagas disease (American trypanosomiasis) is a protozoan infection caused by Trypanosoma cruzi and is the most common cause in Central and South America. Direct myocardial invasion occurs in the acute phase, and after an asymptomatic latency period of decades, chronic Chagas heart disease develops in about 30~40%.

Cardiac sarcoidosis is cardiac involvement by sarcoidosis, a systemic granulomatous disease of unknown cause. Non-caseating epithelioid cell granulomas deposit in the myocardium, conduction system, and pericardium, causing myocardial dysfunction, conduction disturbances, arrhythmias, and sudden death. Myocardial involvement in systemic lupus erythematosus (SLE) is due to immune complex deposition and cytokine-mediated myocardial injury. It is rare but has an important impact on prognosis. Lyme heart disease results from cardiac invasion by B. burgdorferi and is characterized by high-grade atrioventricular block. Diphtheritic myocarditis results when the exotoxin of Corynebacterium diphtheriae inhibits protein synthesis in myocardial cells, causing myocardial injury. It is still an important cause in some regions. Others include toxoplasmosis, trichinosis, and myocardial involvement by cytomegalovirus (CMV) in immunocompromised patients.


3. Genetics

The genetic background of myocarditis in diseases classified elsewhere is determined by the genetic predisposition to the underlying disease. In cardiac sarcoidosis, the genetic predisposition to sarcoidosis itself is important. HLA-DRB1*03 and HLA-DRB1*04 alleles show positive associations with susceptibility to sarcoidosis, and HLA-DRB1*07 and *14 are associated with a protective effect in some studies. Racial differences in HLA types have been proposed as the reason cardiac sarcoidosis is more common in Japanese people.

In Chagas heart disease, only some people infected with T. cruzi progress to chronic heart disease, and genetic factors related to this risk of progression are being studied. Studies suggest that HLA-DR alleles, TNF-α gene polymorphisms, and immune-related genes (FcγR, IL-10, etc.) may be associated with progression of Chagas heart disease. The risk of myocardial involvement in SLE involves the genetic predisposition to SLE itself (C1q, C2, C4A deficiency; HLA-DR3, DR2; TREX1 variants, etc.). Cardiac involvement in Lyme disease is also presumed to be associated with polymorphisms in host immune response genes.


4. General epidemiology

The epidemiology of myocarditis in diseases classified elsewhere differs greatly by underlying disease. Chagas heart disease is the most important cardiovascular public health problem in Central and South America; about 6~8 million people worldwide are infected with T. cruzi, of whom about 30~40% develop chronic Chagas heart disease. It accounts for 30~40% of heart failure causes in some parts of Central and South America and is a major cause of sudden death at age 45 or younger. Due to immigration, cases are also increasing in the United States, Europe, and Asia.

Regarding the prevalence of cardiac sarcoidosis, clinical cardiac involvement occurs in about 5~10% of patients with sarcoidosis, and including asymptomatic cardiac involvement it is estimated to reach about 25%. In Japan, the proportion of sarcoidosis-related sudden death is higher than in the West, and cardiac sarcoidosis is the leading cause of sarcoid death. Lyme heart disease is known to occur in about 1~4% of patients with Lyme disease, with atrioventricular block as the main clinical manifestation. In the United States, about 300~400 cases of Lyme heart disease are reported each year. Clinical myocarditis in SLE is relatively rare, occurring in about 1~5% of SLE patients, but subclinical cardiac involvement is more common.


5. Pathophysiology

The mechanism of myocardial injury differs depending on the underlying disease. The pathophysiology of Chagas myocarditis is complex. In the acute phase, T. cruzi directly invades myocardial cells and macrophages and causes cell destruction through intracellular replication (amastigote form). In the chronic phase, autoimmune mechanisms are more important than direct parasite invasion. Through molecular mimicry between T. cruzi antigens and myocardial proteins (myosin, etc.), autoreactive T cells and autoantibodies attack myocardial cells. In addition, cardiac autonomic neuropathy due to autonomic nerve involvement promotes apoptosis and increases the risk of arrhythmia.

In cardiac sarcoidosis, non-caseating granulomas centered on CD4+ T cells and macrophages deposit in the myocardium and conduction system. Damage to conduction fibers within the granulomas causes atrioventricular block and bundle branch block, and replacement fibrosis of the myocardium forms substrates for reentrant arrhythmias. In Lyme myocarditis, B. burgdorferi directly invades myocardial and conduction system cells or binds to the extracellular matrix, provoking a local inflammatory response. Inflammatory mediators such as IL-1β and TNF-α are secreted and suppress atrioventricular nodal conduction, resulting in atrioventricular block. In diphtheritic myocarditis, diphtheria exotoxin ADP-ribosylates EF-2 (elongation factor 2), blocking protein synthesis in myocardial cells and causing myocardial cell death.


6. Symptoms

The symptoms of myocarditis in diseases classified elsewhere appear as a mixture of systemic symptoms of the underlying disease and symptoms of myocardial involvement. In Chagas heart disease, in the acute phase (immediately after parasite invasion), fever, malaise, facial edema (Romaña sign: conjunctival edema), chest pain due to myocardial inflammation, and palpitations may occur. In the chronic phase, after an asymptomatic period of decades, symptoms of heart failure (dyspnea, reduced exercise tolerance), arrhythmia (palpitations, syncope), and thromboembolism (cerebral infarction, pulmonary embolism) appear. It is not uncommon for sudden death to be the first clinical manifestation.

The most common cardiac symptoms of cardiac sarcoidosis are bradycardia, dizziness, and syncope due to conduction disturbances (high-grade atrioventricular block, bundle branch block). Ventricular tachycardia and ventricular fibrillation are the main causes of sudden death, and heart failure symptoms (dyspnea, lower limb edema) may also occur. The main cardiac manifestation of Lyme heart disease is high-grade atrioventricular block (PR interval prolongation, complete atrioventricular block), accompanied by dizziness, syncope, chest pain, dyspnea, and so on. Atrioventricular block often resolves spontaneously, so temporary pacemaker insertion is sometimes required. Diphtheritic myocarditis appears within 1~2 weeks after infection in the form of heart failure, complete atrioventricular block, or ventricular fibrillation and has a high mortality rate in infants and children.


7. Signs

Physical examination findings in myocarditis in diseases classified elsewhere reflect the underlying disease and the extent of myocardial involvement. In the chronic phase of Chagas heart disease, lateral displacement of the apical impulse due to cardiac enlargement (left ventricular dilated cardiomyopathy), an S3 gallop, and signs of heart failure (pulmonary edema, elevated jugular venous pressure, lower limb edema) appear. An irregular pulse due to arrhythmia is common, and attention is needed to assess the risk of sudden death.

In cardiac sarcoidosis, bradycardia or an irregular pulse (atrioventricular block, ventricular arrhythmia) and signs of heart failure appear. Signs of systemic sarcoidosis (abnormal lung auscultation, skin lesions, eye symptoms, lymphadenopathy) may accompany them. In Lyme heart disease, a diastolic murmur (reduced heart rate due to atrioventricular block) and bradycardia are prominent, and systemic signs of Lyme disease (erythema migrans, joint swelling, facial nerve palsy) may accompany them.


8. Screening

Screening for myocarditis in diseases classified elsewhere consists of evaluating cardiac involvement at diagnosis of the underlying disease and during regular follow-up. In immigrants from or visitors to Chagas-endemic areas (Central and South America), screening by serologic testing (IgG anti-T. cruzi antibodies) is recommended. In particular, Chagas disease should be included in the differential diagnosis when heart failure, arrhythmia, or conduction disturbance is of unknown cause.

In patients diagnosed with sarcoidosis, screening for cardiac sarcoidosis at the initial visit with ECG, echocardiography, and, when needed, cardiac MRI or FDG-PET/CT is recommended. Even without symptoms, cardiac sarcoidosis carries a risk of sudden death, so regular ECG follow-up is needed. When palpitations, dizziness, or syncope develop in residents of or visitors to Lyme-endemic areas, Lyme serology (ELISA followed by Western blot confirmation) is performed. In SLE patients with chest pain, dyspnea, or elevated cardiac enzymes, myocarditis should be included in the differential diagnosis and echocardiography and cardiac MRI performed.


9. Diagnosis

Serologic testing is central to the diagnosis of each underlying disease. Chagas disease is confirmed when positive by 2 or more serologic methods (ELISA, IFA, indirect hemagglutination). For Lyme disease, the standard is two-tier testing with ELISA screening followed by Western blot confirmation. For sarcoidosis, the confirmatory criterion is demonstration of non-caseating granulomas on tissue biopsy (lung, skin, lymph node, or myocardium).

Cardiac MRI is the key test for evaluating the extent and characteristics of myocardial involvement. In Chagas heart disease, an LGE pattern prominent in the inferolateral wall and apex is characteristic. In cardiac sarcoidosis, heterogeneous LGE of the basal lateral wall or interventricular septum is characteristic, and various sites may be involved. FDG-PET/CT is useful in cardiac sarcoidosis for confirming active granulomatous involvement (increased FDG uptake) and assessing treatment response. Endomyocardial biopsy is used to confirm cardiac sarcoidosis, but its sensitivity is low (about 20~30%), so a negative result does not readily exclude it. 24-hour Holter ECG is useful for detecting arrhythmias and conduction disturbances.


10. Treatment

Benznidazole and nifurtimox are used as antiparasitic drugs for Chagas disease. In the acute or early chronic phase they can reduce the parasite burden and slow the progression of heart disease, but in established chronic Chagas heart disease the clinical benefit is limited. For heart failure, GDMT including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists is applied. For arrhythmias, amiodarone is preferred, and pacemaker or ICD implantation is often needed. In end-stage heart failure, heart transplantation is considered.

In cardiac sarcoidosis with conduction disturbances or ventricular arrhythmias, immunosuppressive treatment is started with corticosteroids (prednisone 40~60 mg/day). When active inflammation is confirmed on FDG-PET/CT, it is used to assess treatment response. High-grade atrioventricular block is an indication for permanent pacemaker implantation, and ICD implantation is considered according to sustained ventricular tachycardia or assessment of sudden death risk. For Lyme heart disease, mild cases (first- and second-degree atrioventricular block) are treated with oral doxycycline 100 mg twice daily for 14~21 days, and severe cases (complete atrioventricular block, myocarditis) with intravenous ceftriaxone 2 g/day for 14~21 days. Atrioventricular block mostly resolves with antibiotic treatment.


11. Prognosis

The prognosis of myocarditis in diseases classified elsewhere is determined by the underlying disease and the extent of myocardial involvement. Chagas heart disease is one of the most important causes of heart failure and sudden death in Central and South America. The 5-year mortality of patients who have developed chronic Chagas heart disease reaches about 50%, and the prognosis worsens as heart failure progresses. Elevated BNP, ventricular tachycardia, reduced left ventricular function, and atrial fibrillation are independent poor prognostic factors.

Cardiac sarcoidosis carries a high risk of sudden death due to conduction disturbances and ventricular arrhythmias, and the prognosis is poor if it progresses to heart failure. Prognosis can be improved with appropriate immunosuppressive treatment and device therapy (pacemaker, ICD). In Lyme heart disease, atrioventricular block mostly resolves completely with antibiotic treatment, and the prognosis is very good. Rarely, myocardial injury persists, but permanent sequelae are rare. Diphtheritic myocarditis is recoverable with prompt antitoxin administration and intensive care, but mortality is high if treatment is delayed.


12. Prevention

The key to preventing Chagas disease is control of the vector insects (kissing bugs, Triatoma spp.). This includes improving housing (repairing cracked walls, insecticide treatment), screening of blood donations and transfusions (blood bank testing), and preventing vertical transmission in mothers (testing newborns of infected pregnant women). Transfusion screening in organ transplantation is also important. A vaccine for Chagas disease is currently in development, but none has yet been approved.

To prevent Lyme disease, wearing long sleeves and trousers in tick-infested areas, using DEET- or permethrin-based repellents, and checking the whole body after outdoor activities are recommended. There is currently no direct method of preventing cardiac sarcoidosis, but regular testing to detect cardiac involvement early at the diagnosis of sarcoidosis contributes to preventing serious complications (sudden death). To prevent myocardial involvement in SLE patients, controlling lupus activity, reducing ultraviolet exposure, and maintaining appropriate immunosuppressive treatment are important.


13. References

  1. Nunes MCP, Beaton A, Bhatt DL, et al. (American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee). Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management. Circulation. 2018;138(12):e169-e209. DOI: 10.1161/CIR.0000000000000599. PMID: 30354454.

  2. Birnie DH, Sauer WH, Bogun F, et al. HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm. 2014;11(7):1306-1323. DOI: 10.1016/j.hrthm.2014.03.043. PMID: 24819193.

  3. Costello CM, Steere AC, Pinkston RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. Journal of Infectious Diseases. 1989;159(1):136-139. DOI: 10.1093/infdis/159.1.136. PMID: 2909530.

  4. Rosenbaum MB. Chagasic myocardiopathy. Progress in Cardiovascular Diseases. 1964;7:199-225. DOI: 10.1016/S0033-0620(64)80008-2. PMID: 14171505.

  5. Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart. 2016;102(2):100-106. DOI: 10.1136/heartjnl-2015-307959. PMID: 26643793.

  6. Sauer WH, Stern BJ, Baughman RP, et al. High-dose corticosteroids for refractory cardiac sarcoidosis. Chest. 2005;128(3):1579-1585. DOI: 10.1378/chest.128.3.1579. PMID: 16162762.

  7. Spindler C, Strauss C, Elias M, et al. Lyme carditis: clinical characteristics and follow-up. European Heart Journal. 1998;19(4):614-619. DOI: 10.1053/euhj.1997.0677. PMID: 9597405.

  8. Caforio AL, Mahon NG, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. European Journal of Heart Failure. 2002;4(4):411-417. DOI: 10.1016/s1388-9842(02)00010-6. PMID: 12167381.

  9. Bocchi EA, Braga FGM, Ferreira SMA, et al. III Brazilian Guidelines on Chronic Heart Failure. Arquivos Brasileiros de Cardiologia. 2009;93(1 Suppl 1):1-71. DOI: 10.1590/s0066-782x2009001700001. PMID: 20084303.

  10. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969-1977. DOI: 10.1161/CIRCULATIONAHA.109.851352. PMID: 19884472.